171 / 172
171
199.Kremer JM, Genant HK, Moreland LW, Russell AS, Emery
P, Abud-Mendoza C, et al. Results of a two-year followup
study of patients with rheumatoid arthritis who received a
combination of abatacept and methotrexate. Arthritis Rheum
2008;58:953-63.
200.Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis.
Lancet 2010;376:1094-108.
201. Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell
P. Sulfasalazine for rheumatoid arthritis. Cochrane Database
Syst Rev 2000(2):CD000958.
202.Hamilton J, McInnes IB, Thomson EA, Porter D, Hunter
JA, Madhok R, et al. Comparative study of intramuscular gold
and methotrexate in a rheumatoid arthritis population from a
socially deprived area. Ann Rheum Dis 2001;60:566-72.
203.van der Heijde DM, van Riel PL, Nuver-Zwart IH, van de
Putte LB. Sulphasalazine versus hydroxychloroquine in
rheumatoid arthritis: 3-year follow-up. Lancet 1990;335:539.
204. Kremer JM, Genovese MC, Cannon GW, Caldwell JR,
Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in
patients with active rheumatoid arthritis despite stable doses
of methotrexate. A randomized, double-blind, placebo-
controlled trial. Ann Intern Med 2002;137:726-33.
205. Titton DC, Silveira IG, Louzada-Junior P, Hayata AL,
Carvalho HM, Ranza R, et al. Brazilian biologic registry:
BiobadaBrasil implementation process and preliminary results.
Rev Bras Reumatol 2011;51:152-60.
206.Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y,
Bombardier C, et al. ndirect comparisons of the efficacy of
biological antirheumatic agents in rheumatoid arthritis in
patients with an inadequate response to conventional disease-
modifying antirheumatic drugs or to an anti-tumour necrosis
factor agent: a meta-analysis. Ann Rheum Dis 2011;70:266-71.
207.Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z,
Routh K, et al. Adalimumab, etanercept, infliximab, rituximab